CN104414986B - 一种含有拉米夫定的药物组合物 - Google Patents
一种含有拉米夫定的药物组合物 Download PDFInfo
- Publication number
- CN104414986B CN104414986B CN201310378553.6A CN201310378553A CN104414986B CN 104414986 B CN104414986 B CN 104414986B CN 201310378553 A CN201310378553 A CN 201310378553A CN 104414986 B CN104414986 B CN 104414986B
- Authority
- CN
- China
- Prior art keywords
- lamivudine
- mixed
- pharmaceutical composition
- powder
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title claims abstract description 62
- 229960001627 lamivudine Drugs 0.000 title claims abstract description 62
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000000843 powder Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 21
- 229920002472 Starch Polymers 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000008107 starch Substances 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 20
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 18
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 16
- 239000000741 silica gel Substances 0.000 claims description 15
- 229910002027 silica gel Inorganic materials 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 239000011122 softwood Substances 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 12
- 230000003179 granulation Effects 0.000 claims description 12
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
- CODAYFPFZXWNLD-UHFFFAOYSA-N 2-hydroxypropanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)C(C)O CODAYFPFZXWNLD-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 8
- 239000007779 soft material Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 13
- 239000007884 disintegrant Substances 0.000 abstract description 6
- 239000003995 emulsifying agent Substances 0.000 abstract description 6
- 239000000945 filler Substances 0.000 abstract description 6
- 239000000314 lubricant Substances 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000008279 sol Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CHFYSOCPHBZWAG-UHFFFAOYSA-N 1,3-oxathiolan-2-ylmethanol Chemical compound OCC1OCCS1 CHFYSOCPHBZWAG-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 125000003835 nucleoside group Chemical class 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
原辅料 | 处方1 | 处方2 | 处方3 | 处方4 |
拉米夫定 | 13.00 | 13.00 | 13.00 | 13.00 |
微晶纤维素 | 32.55 | 32.55 | 32.55 | 32.55 |
交联聚维酮 | 6.50 | 6.50 | 6.50 | 6.50 |
硬脂酰延胡索酸钠 | 0 | 3.0 | 5.0 | 7.0 |
聚维酮 | 6.25 | 6.25 | 6.25 | 6.25 |
硬脂酸镁 | 0.65 | 0.65 | 0.65 | 0.65 |
考察项目 | 溶出度(%) | 含量(%) | 有关物质(%) | 异构体(%) |
处方1 | 75.3 | 99.1 | 0.46 | 0.06 |
处方2 | 99.3 | 99.1 | 0.39 | 0.05 |
处方3 | 99.7 | 99.2 | 0.55 | 0.07 |
处方4 | 99.6 | 98.7 | 0.60 | 0.07 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310378553.6A CN104414986B (zh) | 2013-08-27 | 2013-08-27 | 一种含有拉米夫定的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310378553.6A CN104414986B (zh) | 2013-08-27 | 2013-08-27 | 一种含有拉米夫定的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104414986A CN104414986A (zh) | 2015-03-18 |
CN104414986B true CN104414986B (zh) | 2017-04-05 |
Family
ID=52965813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310378553.6A Active CN104414986B (zh) | 2013-08-27 | 2013-08-27 | 一种含有拉米夫定的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104414986B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102144984A (zh) * | 2011-04-06 | 2011-08-10 | 福建广生堂药业有限公司 | 一种易于溶出的拉米夫定片及其制备方法 |
CN102283846A (zh) * | 2011-09-08 | 2011-12-21 | 北京万生药业有限责任公司 | 拉米夫定制剂及其制备方法 |
CN103181910A (zh) * | 2011-12-30 | 2013-07-03 | 北京协和药厂 | 一种拉米夫定片剂及其制备方法 |
US8481554B2 (en) * | 2009-05-27 | 2013-07-09 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
-
2013
- 2013-08-27 CN CN201310378553.6A patent/CN104414986B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8481554B2 (en) * | 2009-05-27 | 2013-07-09 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
CN102144984A (zh) * | 2011-04-06 | 2011-08-10 | 福建广生堂药业有限公司 | 一种易于溶出的拉米夫定片及其制备方法 |
CN102283846A (zh) * | 2011-09-08 | 2011-12-21 | 北京万生药业有限责任公司 | 拉米夫定制剂及其制备方法 |
CN103181910A (zh) * | 2011-12-30 | 2013-07-03 | 北京协和药厂 | 一种拉米夫定片剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104414986A (zh) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105326808B (zh) | 用于清热化痰解毒的胶囊剂 | |
CN101612171B (zh) | 银杏叶提取物缓释微丸及其制备方法 | |
CN102499923B (zh) | 一种药物组合物、其制备方法及用途 | |
CN105640913B (zh) | 一种奥美沙坦酯片及其制备方法 | |
CN104546686B (zh) | 一种枸橼酸莫沙必利共研磨物及其制备方法和含其药物组合物 | |
CN105412026B (zh) | 盐酸阿考替胺片及其制备方法 | |
CN1803180A (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN106214656A (zh) | 一种复方甘草酸苷片的制备及质量控制检测方法 | |
CN105055476B (zh) | 一种血塞通分散片及其制备方法 | |
CN117180337A (zh) | 一种蒙药悬钩子木配方颗粒的制备方法及其指纹图谱构建方法 | |
CN101524398B (zh) | 甘草黄酮的药物用途 | |
CN108057046A (zh) | 一种采用粉末直接压片的金水宝片制备方法 | |
CN104414986B (zh) | 一种含有拉米夫定的药物组合物 | |
CN108125913A (zh) | 一种索非布韦药物制剂 | |
CN107929247A (zh) | 一种布洛肾素那敏片剂组合物及其制备方法 | |
CN109953966A (zh) | 一种含有瑞博西尼的药物组合物及其制备方法 | |
CN102327249B (zh) | 一种拉米夫定片剂组合物及其制备方法 | |
CN109953965A (zh) | 一种含有酒石酸匹莫范色林的药物组合物 | |
CN105168165B (zh) | 一种盐酸乐卡地平片及其制备方法 | |
CN110327304A (zh) | 一种稳定的替格瑞洛片剂组合物、其制备方法和应用 | |
CN109674756B (zh) | 一种盐酸克仑特罗片及其制备方法 | |
CN107349185A (zh) | 一种恩曲他滨片剂以及制备方法 | |
CN105640950B (zh) | 一种复方α‐酮酸片的制备方法 | |
CN109953962A (zh) | 一种含有地夫可特的药物组合物及其制备方法 | |
CN1286452C (zh) | 鸡胆浸膏分散片及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination containing lamivudine Effective date of registration: 20231226 Granted publication date: 20170405 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000149 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |